S. Highfill

发表

Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.

M. Farrar, C. Bucher, A. Panoskaltsis-Mortari, 2010, Blood.

Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.

D. Munn, J. Tolar, J. Serody, 2010, Blood.

High efficiency closed-system gene transfer using automated spinoculation

D. Stroncek, Yihua Cai, P. Jin, 2021, Journal of translational medicine.

Advances in T-cell Immunotherapies.

Opal L. Reddy, D. Stroncek, S. Highfill, 2019, Hematology/oncology clinics of North America.

Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses1

C. Desponts, W. Kerr, J. Brayer, 2004, The Journal of Immunology.

A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy

T. Fry, C. Mackall, J. Lai, 2013, Journal of immunotherapy.

BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study

Bryan R. Smith, D. Reich, Omar Al-Louzi, 2021, The Lancet Neurology.

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

S. Steinberg, M. Stetler-Stevenson, D. Stroncek, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells

Yong Gu Lee, Nathan H. Roy, S. Grupp, 2021, Nature Network Boston.

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence

D. Dimitrov, M. Stetler-Stevenson, T. Fry, 2019, Clinical Cancer Research.

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies

D. Stroncek, S. Highfill, Hannah W Song, 2022, International reviews of immunology.

Overcoming Challenges in Process Development of Cellular Therapies

D. Stroncek, S. Highfill, 2019, Current Hematologic Malignancy Reports.

Novel DNA-based T-Cell Activator Promotes Rapid T-Cell Activation and Expansion

D. Stroncek, E. Loghin, S. Highfill, 2020, Journal of immunotherapy.

CAR T-Cell: Cell Processing Laboratory Considerations

D. Stroncek, P. Jin, S. Highfill, 2020 .

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

D. Stroncek, W. Flegel, P. Jin, 2020, Transfusion.

Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control

D. Stroncek, Yihua Cai, P. Jin, 2021, Journal of translational medicine.

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules

D. Stroncek, S. Feldman, Christian S. Hinrichs, 2018, Journal of Translational Medicine.

Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

P. Dagur, D. Stroncek, T. Fry, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use

K. Zoon, D. Stroncek, C. Annunziata, 2019, Journal of Translational Medicine.

Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products

D. Stroncek, H. Lei, Yihua Cai, 2020, Journal of Translational Medicine.

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation

M. Stetler-Stevenson, T. Fry, C. Mackall, 2022, Journal for ImmunoTherapy of Cancer.

Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis

J. Modiano, D. Bellgrau, M. G. O’Sullivan, 2014, PloS one.

Cell Responses SHIP-Deficient Mice Represses Allogeneic T Expansion of Myeloid Suppressor Cells in

W. Kerr, J. Brayer, E. Sotomayor, 2013 .

mechanism that is up-regulated by interleukin-13 dependent - graft-versus-host disease (GVHD) via an arginase-1 Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit

D. Munn, J. Serody, B. Koehn, 2011 .

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

D. Munn, J. Tolar, B. Levine, 2009, Blood.

Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of LAD-1.

M. Pirooznia, K. Keyvanfar, D. Kuhns, 2022, Human gene therapy.

CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort

D. Stroncek, T. Fry, Jiaqiang Ren, 2017 .

transplantation and enhance T-cell reconstitution following murine bone marrow protect against conditioning regimen-induced thymic epithelial damage Keratinocyte growth factor and androgen blockade work in concert to

B. Blazar, P. Taylor, R. Boyd, 2013 .

Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation.

G. Holländer, B. Blazar, P. Taylor, 2008, Blood.

Keratinocyte Growth Factor and Androgen Blockade Work in Concert to Protect Against Conditioning Regimen-Induced Thymic Epithelial Damage and Enhance T-Cell Reconstitution Following Murine Bone Marrow Transplantation

G. Holländer, B. Blazar, P. Taylor, 2008 .

Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming.

J. Tolar, B. Blazar, P. Taylor, 2009, Blood.

Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia (AML) Running title: PD-1 blockade and adoptive CTL therapy for AML

D. Munn, J. Tolar, C. June, 2010 .

Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products

D. Stroncek, Yihua Cai, J. Kochenderfer, 2022, Journal of Translational Medicine.

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells

P. Jin, S. Highfill, H. Shalabi, 2022, Molecular therapy. Methods & clinical development.

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas

R. Orentas, C. Mackall, M. Tsokos, 2016, Cancer Immunology Research.

Effects of starting cellular material composition on chimeric antigen receptor T‐cell expansion and characteristics

D. Stroncek, J. Kochenderfer, P. Jin, 2019, Transfusion.

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

J. Lack, D. Stroncek, W. Faquin, 2021, Nature Medicine.

Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells

D. Stroncek, T. Fry, A. Kizhakeyil, 2021, Molecular Cancer Therapeutics.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Amber J. Giles, R. Kaplan, C. Mackall, 2014, Science Translational Medicine.

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

S. Steinberg, K. Zoon, D. Stroncek, 2018, Journal of Translational Medicine.

Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument

Opal L. Reddy, D. Stroncek, C. Mackall, 2019, Clinical hematology international.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

D. Munn, J. Tolar, B. Levine, 2010, Blood.

Optimizing a fully automated and closed system process for red blood cell reduction of human bone marrow products.

D. Stroncek, Yihua Cai, P. Jin, 2023, Cytotherapy.

Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7

W. Faquin, Christian S. Hinrichs, S. Highfill, 2018, Blood.

Removal Of Myeloid Cells From Autologous Leukocytes Used For Chimeric Antigen Receptor (Car) T Cell Manufacturing Improves Final Product Consistency And Yields

M. Sabatino, D. Stroncek, C. Mackall, 2017 .

High efficiency closed-system gene transfer using automated spinoculation

D. Stroncek, Yihua Cai, P. Jin, 2021, Journal of Translational Medicine.

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells

M. Sabatino, R. Kaplan, D. Stroncek, 2017, Journal of Translational Medicine.

Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells.

J. Berzofsky, A. Remaley, Yingdong Zhao, 2018, Cytotherapy.

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

S. Rosenberg, T. Lowe, J. Yang, 2021, Blood.

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

S. Rosenberg, J. Yang, M. Stetler-Stevenson, 2020 .

Very Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy for Prevention of Viral Infection after Allogeneic T Cell Depleted Stem Cell Transplantation

M. Sabatino, P. Muranski, A. Barrett, 2018, Blood.

Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity

T. Olsson, L. Alfredsson, I. Kockum, 2013, Proceedings of the National Academy of Sciences.

Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells.

E. Ruppin, S. Steinberg, N. Taylor, 2021, Blood.

Deregulated expression of LRBA facilitates cancer cell growth

T. Yeatman, Tien-chi Pan, A. Ramne, 2004, Oncogene.

Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

Amber J. Giles, R. Kaplan, D. Lyden, 2016, Cancer research.

Immunomagnetic B cell isolation as a tool to study blood cell subsets and enrich B cell transcripts

S. Highfill, Huizhi Zhou, Ryan Baumann, 2021, BMC research notes.

Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays

D. Stroncek, P. Jin, S. Highfill, 2023, Cytotherapy.

S. Steinberg, K. Zoon, D. Stroncek, 2018, Journal of translational medicine.

Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use

K. Zoon, D. Stroncek, C. Annunziata, 2019, Journal of Translational Medicine.

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells

M. Sabatino, R. Kaplan, D. Stroncek, 2017, Journal of Translational Medicine.

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Nathan H. Roy, S. Grupp, C. June, 2019, Blood.

NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease.

Linhong Li, D. Kuhns, D. Stroncek, 2020, Blood advances.

CD19/22 CAR T-cells in Children and Young Adults with B-ALL: Phase I Results and Development of a Novel Bicistronic CAR.

S. Steinberg, G. Altan-Bonnet, D. Stroncek, 2022, Blood.

Single cell sequencing reveals gene expression signatures associated with bone marrow stromal cell subpopulations and time in culture

Yingdong Zhao, D. Stroncek, Jinguo Chen, 2019, Journal of Translational Medicine.

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

D. Stroncek, S. Highfill, P. Tembhare, 2022, Blood.

A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).

Brad J. Wood, Mitchell Ho, T. Greten, 2023, Journal of Clinical Oncology.

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

D. Dimitrov, J. Maris, B. Gryder, 2023, Cell reports. Medicine.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

D. Munn, J. Tolar, B. Levine, 2009, Blood.

Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma

A. Gentles, H. Maecker, B. Sahaf, 2022, Cancer Research.

Deciphering the importance of culture pH on CD22 CAR T-cells characteristics

S. Highfill, L. Shao, S. Frodigh, 2024, Journal of translational medicine.

Assessment and comparison of viability assays for cellular products.

S. Highfill, L. Moses, Jinxia Ma, 2023, Cytotherapy.

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

S. Harmon, B. Turkbey, H. Maecker, 2023, Cancer cell.

CAR-T cell expansion platforms yield distinct T cell differentiation states.

S. Highfill, V. Fellowes, L. Shao, 2024, Cytotherapy.

Point-of-care cell therapy manufacturing; it’s not for everyone

D. Stroncek, R. Somerville, S. Highfill, 2022, Journal of translational medicine.

Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia

J. Kochenderfer, S. Highfill, V. Fellowes, 2024, Molecular therapy. Methods & clinical development.

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.

S. Highfill, E. Cherkasova, Timothy T. Spear, 2024, Journal for immunotherapy of cancer.